Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2021 | High-risk disease biology in multiple myeloma

Gordon Cook • 30 Apr 2021
COMy 2021
Multiple Myeloma Antibodies Dexamethasone Eculizumab Lenalidomide

Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses the importance of identifying patients with multiple myeloma with high-risk disease, based on clinical as well genomic features. Despite previous exclusion from clinical trials, recent assessments of T-cell redirecting therapies have included patients with clinical high-risk disease and such patients receiving lenalidomide, dexamethasone, and eculizumab have shown similar responses to patients without high-risk markers. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.

More from Gordon Cook

2:13
How immunotherapies are changing the myeloma treatment landscape & future outlooks
Gordon Cook • 28 Sep 2023
4:03
Developments in assessing frailty in patients with multiple myeloma
Gordon Cook • 28 Sep 2023
1:05
Considerations for frailty adapted treatment approaches in multiple myeloma
Gordon Cook • 28 Sep 2023
3:23
MRD-directed trials & achieving MRD negativity in patients with high-risk multiple myeloma
Gordon Cook • 26 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals